GeoVax Labs, Inc. (Nasdaq: GOVX) announced on August 6, 2026, the completion of critical manufacturing, regulatory, clinical, and preclinical milestones for its GEO-MVA vaccine program. These milestones position the company to initiate a pivotal Phase 3 immune-bridging study in the fourth quarter of 2026, a key step toward regulatory registration and commercialization of its mpox/smallpox vaccine.
The company reported that it has successfully manufactured, filled, packaged, and released GMP clinical product for the upcoming study, fulfilling a major requirement for clinical development. Regulatory alignment was achieved through European Medicines Agency (EMA) Scientific Advice, supporting an expedited immune-bridging pathway that compares GEO-MVA with the licensed MVA-BN vaccine. Clinical operations have also advanced with CRO engagement and site identification for the planned 500-participant study.
Notably, a comparative nonclinical immunogenicity study demonstrated that GEO-MVA generated robust orthopoxvirus-specific immune responses when evaluated against Imvanex® (MVA-BN), using both binding and neutralizing antibody assays. These data strengthen confidence in the vaccine's potential to elicit protective immunity.
David A. Dodd, Chairman and CEO of GeoVax, emphasized the significance of these achievements: "Completion of these milestones marks a significant inflection point for the GEO-MVA program as we prepare to initiate our pivotal immune-bridging study later this year. We have systematically executed the manufacturing, regulatory, clinical and scientific activities required to support successful study completion, preparing for regulatory registration and ultimate commercialization."
The GEO-MVA program is being developed to expand global manufacturing capacity for non-replicating MVA vaccines, addressing government preparedness needs and future procurement opportunities for mpox/smallpox vaccines. In parallel with clinical development, GeoVax is engaged in discussions with government agencies and international preparedness organizations regarding long-term supply requirements.
The pivotal Phase 3 study is designed to compare immune responses generated by GEO-MVA with those of MVA-BN using established neutralizing antibody endpoints. Results are expected in mid-2027. Successful completion could position GEO-MVA as a strategic asset for biosecurity and orthopoxvirus preparedness.
GeoVax remains focused on advancing GEO-MVA under an expedited regulatory pathway, with the goal of providing an additional reliable source of this critical vaccine. The company also continues development of its oncology program, Gedeptin®, which is being explored for combination with immune checkpoint inhibitors.
For more information about GeoVax and its programs, visit GeoVax's website.
